Posted by admin on Aug 20th, 2022

Atrion (NASDAQ:ATRI – Get Rating) and LMF Acquisition Opportunities (NASDAQ:LMAO – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

This table compares Atrion and LMF Acquisition Opportunities’ net margins, return on equity and return on assets.

This table compares Atrion and LMF Acquisition Opportunities’ top-line revenue, earnings per share (EPS) and valuation.

Atrion has higher revenue and earnings than LMF Acquisition Opportunities.

Atrion has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, LMF Acquisition Opportunities has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500.

77.4% of Atrion shares are owned by institutional investors. Comparatively, 79.3% of LMF Acquisition Opportunities shares are owned by institutional investors. 22.7% of Atrion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

This is a breakdown of recent recommendations and price targets for Atrion and LMF Acquisition Opportunities, as reported by MarketBeat.

Atrion beats LMF Acquisition Opportunities on 7 of the 8 factors compared between the two stocks.

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

LMF Acquisition Opportunities, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Tampa, Florida.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Ascend Wellness (AAWH) versus The Competition Head to Head Comparison

Stem (NYSE:STEM) Shares Down 11% Following Insider Selling